Jacques Young

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2053387/publications.pdf

Version: 2024-02-01

229 papers	15,110 citations	11651 70 h-index	22166 113 g-index
238 all docs	238 docs citations	238 times ranked	10749 citing authors

#	Article	IF	Citations
1	Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nature Genetics, 2003, 33, 463-465.	21.4	764
2	European Consensus Statement on congenital hypogonadotropic hypogonadismâ€"pathogenesis, diagnosis and treatment. Nature Reviews Endocrinology, 2015, 11, 547-564.	9.6	664
3	A Family with Hypogonadotropic Hypogonadism and Mutations in the Gonadotropin-Releasing Hormone Receptor. New England Journal of Medicine, 1997, 337, 1597-1603.	27.0	473
4	Kallmann Syndrome: Mutations in the Genes Encoding Prokineticin-2 and Prokineticin Receptor-2. PLoS Genetics, 2006, 2, e175.	3.5	391
5	Neurosteroids: Deficient cognitive performance in aged rats depends on low pregnenolone sulfate levels in theâ€‰hippocampus. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 14865-14870.	7.1	284
6	Isolated Familial Hypogonadotropic Hypogonadism and aGNRH1Mutation. New England Journal of Medicine, 2009, 360, 2742-2748.	27.0	247
7	Clinical Management of Congenital Hypogonadotropic Hypogonadism. Endocrine Reviews, 2019, 40, 669-710.	20.1	244
8	Large Genomic Rearrangements in the Hepatocyte Nuclear Factor-1Î² (TCF2) Gene Are the Most Frequent Cause of Maturity-Onset Diabetes of the Young Type 5. Diabetes, 2005, 54, 3126-3132.	0.6	236
9	Ketoconazole in Cushing's Disease: Is It Worth a Try?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1623-1630.	3.6	231
10	Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 Are Identified in Individuals with Congenital Hypogonadotropic Hypogonadism. American Journal of Human Genetics, 2013, 92, 725-743.	6.2	227
11	TAC3andTACR3Defects Cause Hypothalamic Congenital Hypogonadotropic Hypogonadism in Humans. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2287-2295.	3.6	214
12	The Postmenopausal Ovary Is Not a Major Androgen-Producing Gland. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5060-5066.	3.6	193
13	SEMA3A, a Gene Involved in Axonal Pathfinding, Is Mutated in Patients with Kallmann Syndrome. PLoS Genetics, 2012, 8, e1002896.	3.5	190
14	Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2796-2804.	3.6	187
15	New insights in prolactin: pathological implications. Nature Reviews Endocrinology, 2015, 11, 265-275.	9.6	178
16	Loss-of-Function Mutations in SOX10 Cause Kallmann Syndrome with Deafness. American Journal of Human Genetics, 2013, 92, 707-724.	6.2	177
17	Intraadrenal Corticotropin in Bilateral Macronodular Adrenal Hyperplasia. New England Journal of Medicine, 2013, 369, 2115-2125.	27.0	176
18	Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. European Journal of Endocrinology, 2010, 163, 193-200.	3.7	167

#	Article	IF	Citations
19	Neurosteroids: Biosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. Journal of Steroid Biochemistry and Molecular Biology, 1991, 40, 71-81.	2.5	158
20	Germline AIP Mutations in Apparently Sporadic Pituitary Adenomas: Prevalence in a Prospective Single-Center Cohort of 443 Patients. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E663-E670.	3.6	157
21	SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer, 2014, 135, 2711-2720.	5.1	155
22	X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocrine-Related Cancer, 2015, 22, 353-367.	3.1	151
23	Prolactin â€" a pleiotropic factor in health and disease. Nature Reviews Endocrinology, 2019, 15, 356-365.	9.6	148
24	Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. Journal of Clinical Investigation, 2012, 122, 3791-3795.	8.2	147
25	Lack of Androgen Receptor Expression in Sertoli Cells Accounts for the Absence of Anti-Mullerian Hormone Repression during Early Human Testis Development. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1818-1825.	3.6	146
26	The Same Molecular Defects of the Gonadotropin-Releasing Hormone Receptor Determine a Variable Degree of Hypogonadism in Affected Kindred¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 567-572.	3.6	145
27	Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology, 2006, 65, 536-543.	2.4	142
28	Kallmann syndrome: 14 novel mutations inKAL1andFGFR1(KAL2). Human Mutation, 2005, 25, 98-99.	2.5	141
29	Kisspeptin Restores Pulsatile LH Secretion in Patients with Neurokinin B Signaling Deficiencies: Physiological, Pathophysiological and Therapeutic Implications. Neuroendocrinology, 2013, 97, 193-202.	2.5	137
30	Acromegaly. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 555-574.	4.7	133
31	SEMA3A deletion in a family with Kallmann syndrome validates the role of semaphorin 3A in human puberty and olfactory system development. Human Reproduction, 2012, 27, 1460-1465.	0.9	133
32	GENETICS IN ENDOCRINOLOGY: Genetic counseling for congenital hypogonadotropic hypogonadism and Kallmann syndrome: new challenges in the era of oligogenism and next-generation sequencing. European Journal of Endocrinology, 2018, 178, R55-R80.	3.7	128
33	Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?. European Journal of Endocrinology, 2010, 162, 1147-1153.	3.7	126
34	A Comparative Phenotypic Study of Kallmann Syndrome Patients Carrying Monoallelic and Biallelic Mutations in the Prokineticin 2 or Prokineticin Receptor 2 Genes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 659-669.	3.6	124
35	Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism. Nature Reviews Endocrinology, 2012, 8, 172-182.	9.6	124
36	Testicular Anti-MÃ¼llerian Hormone Secretion Is Stimulated by Recombinant Human FSH in Patients with Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 724-728.	3.6	122

#	Article	IF	Citations
37	MANAGEMENT OF ENDOCRINE DISEASE: Cushingâ€™s syndrome due to ectopic ACTH secretion: an expert operational opinion. European Journal of Endocrinology, 2020, 182, R29-R58.	3.7	120
38	Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3450-3458.	3.6	118
39	The Same Molecular Defects of the Gonadotropin-Releasing Hormone Receptor Determine a Variable Degree of Hypogonadism in Affected Kindred. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 567-572.	3.6	118
40	Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2578-2585.	3.6	116
41	Osilodrostat, a potent oral 11Î²-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushingâ€™s disease. Pituitary, 2016, 19, 138-148.	2.9	116
42	Pregnenolone, dehydroepiandrosterone, and their sulfate and fatty acid esters in the rat brain. Steroids, 1989, 54, 287-297.	1.8	115
43	Kallmannâ€™s Syndrome: A Comparison of the Reproductive Phenotypes in Men Carrying KAL1 and FGFR1/KAL2 Mutations. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 758-763.	3.6	109
44	<scp>IGSF</scp> 10 mutations dysregulate gonadotropinâ€releasing hormone neuronal migration resulting in delayed puberty. EMBO Molecular Medicine, 2016, 8, 626-642.	6.9	109
45	Biosynthesis and assay of neurosteroids in rats and mice: Functional correlates. Journal of Steroid Biochemistry and Molecular Biology, 1995, 53, 355-360.	2.5	104
46	Non-syndromic congenital hypogonadotropic hypogonadism: clinical presentation and genotypeâ€“phenotype relationships. European Journal of Endocrinology, 2010, 162, 835-851.	3.7	104
47	One-Year Progression-Free Survival of Therapy-Naive Patients With Malignant Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4006-4012.	3.6	102
48	Normal Pituitary Hypertrophy as a Frequent Cause of Pituitary Incidentaloma: A Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3009-3015.	3.6	101
49	Approach to the Male Patient with Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 707-718.	3.6	100
50	Identification of Multiple Gene Mutations Accounts for a new Genetic Architecture of Primary Ovarian Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4541-4550.	3.6	99
51	Pituitary Magnetic Resonance Imaging Findings Do Not Influence Surgical Outcome in Adrenocorticotropin-Secreting Microadenomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3371-3376.	3.6	94
52	Clinical Outcome, Hormonal Status, Gonadotrope Axis, and Testicular Function in 219 Adult Men Born With Classic 21-Hydroxylase Deficiency. A French National Survey. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2303-2313.	3.6	94
53	Functional hypothalamic amenorrhoea: a partial and reversible gonadotrophin deficiency of nutritional origin. Clinical Endocrinology, 1999, 50, 229-235.	2.4	92
54	Effects of Testosterone on Ventricular Repolarization in Hypogonadic Men. American Journal of Cardiology, 2009, 103, 887-890.	1.6	90

#	Article	IF	Citations
55	Long-Term Outcome of Patients with Acromegaly and Congestive Heart Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5308-5313.	3.6	89
56	Panhypopituitarism as a Model to Study the Metabolism of Dehydroepiandrosterone (DHEA) in Humans. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2578-2585.	3.6	86
57	Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology, 2015, 172, 473-481.	3.7	84
58	Macroprolactinomas in Children and Adolescents: Factors Associated With the Response to Treatment in 77 Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1177-1186.	3.6	83
59	Normosmic Congenital Hypogonadotropic Hypogonadism Due to TAC3/TACR3 Mutations: Characterization of Neuroendocrine Phenotypes and Novel Mutations. PLoS ONE, 2011, 6, e25614.	2.5	83
60	NovelFGFR1 sequence variants in Kallmann syndrome, and genetic evidence that the FGFR1c isoform is required in olfactory bulb and palate morphogenesis. Human Mutation, 2007, 28, 97-98.	2.5	81
61	The Prevalence ofCHD7Missense Versus Truncating Mutations Is Higher in Patients With Kallmann Syndrome Than in Typical CHARGE Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2138-E2143.	3.6	81
62	Unilateral Adrenalectomy as a First-Line Treatment of Cushing's Syndrome in Patients With Primary Bilateral Macronodular Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4417-4424.	3.6	79
63	AntimÃ¼llerian Hormone in Patients with Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2696-2699.	3.6	77
64	Female Gonadal Function before and after Treatment of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4518-4525.	3.6	77
65	Overexpression of Serotonin4 Receptors in Cisapride-Responsive Adrenocorticotropin-Independent Bilateral Macronodular Adrenal Hyperplasia Causing Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 248-254.	3.6	75
66	Type A Insulin Resistance Syndrome Revealing a Novel Lamin A Mutation. Diabetes, 2005, 54, 1873-1878.	0.6	75
67	The Paradoxical Increase in Cortisol Secretion Induced by Dexamethasone in Primary Pigmented Nodular Adrenocortical Disease Involves a Glucocorticoid Receptor-Mediated Effect of Dexamethasone on Protein Kinase A Catalytic Subunits. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2406-2413.	3.6	75
68	Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocrine-Related Cancer, 2013, 20, 371-381.	3.1	75
69	Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3239-3244.	3.6	72
70	Molecular Screening for a Personalized Treatment Approach in Advanced Adrenocortical Cancer. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4080-4088.	3.6	72
71	Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction. Clinical Endocrinology, 2000, 53, 445-451.	2.4	70
72	Suppressive effects of dehydroepiandrosterone and 3Î²-methyl-androst-5-en-17-one on attack towards lactating female intruders by castrated male mice. II. Brain neurosteroids. Biochemical and Biophysical Research Communications, 1991, 174, 892-897.	2.1	69

#	Article	IF	Citations
73	Failure of combined follicle-stimulating hormone-testosterone administration to initiate and/or maintain spermatogenesis in men with hypogonadotropic hypogonadism [published erratum appears in J Clin Endocrinol Metab 1994 Apr;78(4):846]. Journal of Clinical Endocrinology and Metabolism, 1993, 77, 1545-1549.	3.6	66
74	The impact of a pure antiâ€androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clinical Endocrinology, 1993, 39, 157-162.	2.4	65
75	Cardiac Structure and Function in Cushing's Syndrome: A Cardiac Magnetic Resonance Imaging Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2144-E2153.	3.6	65
76	New mutations in non-syndromic primary ovarian insufficiency patients identified via whole-exome sequencing. Human Reproduction, 2017, 32, 1512-1520.	0.9	65
77	Neurosteroids: pregnenolone in human sciatic nerves.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 6790-6793.	7.1	64
78	Antimullerian Hormone in Patients with Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2696-2699.	3.6	64
79	Ectopic ACTH Syndrome in Children and Adolescents. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1213-1222.	3.6	63
80	Xp22.3 deletions in isolated familial Kallmann's syndrome. Journal of Clinical Endocrinology and Metabolism, 1993, 76, 827-831.	3.6	63
81	Different phenotypes in a family with androgen insensitivity caused by the same M780I point mutation in the androgen receptor gene. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2994-2998.	3.6	63
82	Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1772-1780.	6.4	62
83	Non-invasive Diagnostic Strategy in ACTH-dependent Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3273-3284.	3.6	62
84	Comparison of fast Fourier transform and autoregressive spectral analysis for the study of heart rate variability in diabetic patients. International Journal of Cardiology, 2005, 104, 307-313.	1.7	60
85	The Antigonadotropic Activity of a 19-Nor-Progesterone Derivative Is Exerted Both at the Hypothalamic and Pituitary Levels in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4191-4196.	3.6	57
86	No Evidence of a Detrimental Effect of Cabergoline Therapy on Cardiac Valves in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1714-E1719.	3.6	57
87	Anti-MÃ¼llerian Hormone and Ovarian Morphology in Women With Isolated Hypogonadotropic Hypogonadism/Kallmann Syndrome: Effects of Recombinant Human FSH. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1102-1111.	3.6	55
88	ATG7 and ATG9A loss-of-function variants trigger autophagy impairment and ovarian failure. Genetics in Medicine, 2019, 21, 930-938.	2.4	55
89	The Postmenopausal Ovary Is Not a Major Androgen-Producing Gland. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5060-5066.	3.6	55
90	McCune-Albright Syndrome and Acromegaly: Effects of Hypothalamopituitary Radiotherapy and/or Pegvisomant in Somatostatin Analog-Resistant Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4957-4961.	3.6	54

#	Article	IF	Citations
91	Human fetal testis: source of estrogen and target of estrogen action. Human Reproduction, 2007, 22, 1885-1892.	0.9	54
92	Endocrine Effects of the Tyrosine Kinase Inhibitor Vandetanib in Patients Treated for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2741-2749.	3.6	54
93	Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine-Related Cancer, 2010, 17, 797-807.	3.1	52
94	Evidence for DNA-Binding Domainâ€“Ligand-Binding Domain Communications in the Androgen Receptor. Molecular and Cellular Biology, 2012, 32, 3033-3043.	2.3	52
95	Aromatase expression in a feminizing adrenocortical tumor. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3173-3176.	3.6	52
96	PCOS and Hyperprolactinemia: what do we know in 2019?. Clinical Medicine Insights Reproductive Health, 2019, 13, 117955811987192.	3.9	51
97	A new FSHÎ² mutation in a 29-year-old woman with primary amenorrhea and isolated FSH deficiency: functional characterization and ovarian response to human recombinant FSH. European Journal of Endocrinology, 2010, 162, 633-641.	3.7	50
98	High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. European Journal of Endocrinology, 2012, 166, 261-268.	3.7	50
99	Neurosteroids in the mouse brain: Behavioral and pharmacological effects of a 3Î²-hydroxysteroid dehydrogenase inhibitor. Steroids, 1996, 61, 144-149.	1.8	49
100	Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clinical Endocrinology, 2006, 64, 110-113.	2.4	48
101	Familial Glucocorticoid Receptor Haploinsufficiency by Non-Sense Mediated mRNA Decay, Adrenal Hyperplasia and Apparent Mineralocorticoid Excess. PLoS ONE, 2010, 5, e13563.	2.5	48
102	New NOBOX Mutations Identified in a Large Cohort of Women With Primary Ovarian Insufficiency Decrease KIT-L Expression. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 994-1001.	3.6	48
103	New MCM8 mutation associated with premature ovarian insufficiency and chromosomal instability in a highly consanguineous Tunisian family. Fertility and Sterility, 2017, 108, 694-702.	1.0	48
104	Pitfall of Petrosal Sinus Sampling in a Cushing's Syndrome Secondary to Ectopic Adrenocorticotropin-Corticotropin Releasing Hormone (ACTH-CRH) Secretion. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 305-308.	3.6	48
105	Prevalence ofKISS1 Receptormutations in a series of 603 patients with normosmic congenital hypogonadotrophic hypogonadism and characterization of novel mutations: a single-centre study. Human Reproduction, 2016, 31, 1363-1374.	0.9	47
106	Insulin-like Peptide 3 (INSL3) in Men With Congenital Hypogonadotropic Hypogonadism/Kallmann Syndrome and Effects of Different Modalities of Hormonal Treatment: A Single-Center Study of 281 Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E268-E275.	3.6	46
107	Oneâ€year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes. Diabetes, Obesity and Metabolism, 2016, 18, 693-697.	4.4	46
108	Hepatic safety of ketoconazole in Cushingâ€™s syndrome: results of a Compassionate Use Programme in France. European Journal of Endocrinology, 2018, 178, 447-458.	3.7	46

#	Article	IF	Citations
109	Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. European Journal of Endocrinology, 2015, 173, 693-702.	3.7	44
110	Very low frequency of germline GPR101 genetic variation and no biallelic defects with AIP in a large cohort of patients with sporadic pituitary adenomas. European Journal of Endocrinology, 2016, 174, 523-530.	3.7	44
111	Prolactinoma andÂestrogens: pregnancy, contraception andÂhormonal replacement therapy. Annales D'Endocrinologie, 2007, 68, 106-112.	1.4	43
112	Kallmann Syndrome Caused by Mutations in the <i>PROK2</i> and <i>PROKR2</i> Genes: Pathophysiology and Genotype-Phenotype Correlations. Frontiers of Hormone Research, 2010, 39, 121-132.	1.0	42
113	Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. European Journal of Endocrinology, 1999, 140, 187-191.	3.7	39
114	Male acquired hypogonadotropic hypogonadism: Diagnosis and treatment. Annales D'Endocrinologie, 2012, 73, 141-146.	1.4	38
115	Two Families with Normosmic Congenital Hypogonadotropic Hypogonadism and Biallelic Mutations in KISS1R (KISS1 Receptor): Clinical Evaluation and Molecular Characterization of a Novel Mutation. PLoS ONE, 2013, 8, e53896.	2.5	38
116	Kallmann syndrome with FGFR1 and KAL1 mutations detected during fetal life. Orphanet Journal of Rare Diseases, 2015, 10, 71.	2.7	38
117	Sex Steroids, Precursors, and Metabolite Deficiencies in Men With Isolated Hypogonadotropic Hypogonadism and Panhypopituitarism: A GCMS-Based Comparative Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E292-E296.	3.6	38
118	Hypothalamic-Pituitary-Ovarian Axis Reactivation by Kisspeptin-10 in Hyperprolactinemic Women With Chronic Amenorrhea. Journal of the Endocrine Society, 2017, 1, 1362-1371.	0.2	38
119	Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent Cushingâ€™s syndrome. JCI Insight, 2017, 2, .	5.0	38
120	Preoperative medical treatment in Cushingâ€™s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	3.7	37
121	Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?. Hormones and Cancer, 2011, 2, 363-371.	4.9	36
122	Interferon-Î±-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Gravesâ€™ disease. European Journal of Endocrinology, 2006, 154, 367-372.	3.7	35
123	Congenital Hypogonadotropic Hypogonadism Due to GNRH Receptor Mutations in Three Brothers Reveal Sites Affecting Conformation and Coupling. PLoS ONE, 2012, 7, e38456.	2.5	35
124	Congenital hypogonadotropic hypogonadism in females: Clinical spectrum, evaluation and genetics. Annales D'Endocrinologie, 2010, 71, 158-162.	1.4	34
125	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 813-824.	11.4	34
126	Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. Melanoma Research, 2017, 27, 649-652.	1.2	33

#	Article	IF	Citations
127	An ancient founder mutation in PROKR2 impairs human reproduction. Human Molecular Genetics, 2012, 21, 4314-4324.	2.9	31
128	Computed Tomography of the Anterior Skull Base in Kallmann Syndrome Reveals Specific Ethmoid Bone Abnormalities Associated With Olfactory Bulb Defects. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E537-E546.	3.6	31
129	Autoantibodies interacting with purified native thyrotropin receptor. FEBS Journal, 2001, 265, 1022-1031.	0.2	30
130	Estradiol levels in men with congenital hypogonadotropic hypogonadism and the effects ofÂdifferent modalities of hormonal treatment. Fertility and Sterility, 2011, 95, 2324-2329.e3.	1.0	30
131	Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2890-2898.	3.6	30
132	Normal Pituitary Hypertrophy as a Frequent Cause of Pituitary Incidentaloma: A Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3009-3015.	3.6	29
133	Mitotane for 21-Hydroxylase Deficiency in an Infertile Man. New England Journal of Medicine, 2014, 371, 2042-2044.	27.0	28
134	Classification of Patients With GH Disorders May Vary According to the IGF-I Assay. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2844-2852.	3.6	28
135	Developing and evaluating rare disease educational materials co-created by expert clinicians and patients: the paradigm of congenital hypogonadotropic hypogonadism. Orphanet Journal of Rare Diseases, 2017, 12, 57.	2.7	26
136	BMPR1A and BMPR1B Missense Mutations Cause Primary Ovarian Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1449-e1457.	3.6	26
137	Free Luteinizing-Hormone Beta-Subunit in Normal Subjects and Patients with Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1397-1402.	3.6	25
138	Absence of activating mutations in the GnRH receptor gene in human pituitary gonadotroph adenomas. European Journal of Endocrinology, 1998, 139, 157-160.	3.7	25
139	Hypogonadotropic hypogonadism as a model of post-natal testicular anti-MÃ¼llerian hormone secretion in humans. Molecular and Cellular Endocrinology, 2003, 211, 51-54.	3.2	25
140	Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. Annales D'Endocrinologie, 2010, 71, 14-18.	1.4	25
141	Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas. Journal of the Endocrine Society, 2017, 1, 221-230.	0.2	25
142	Genetics defects in GNRH1: A paradigm of hypothalamic congenital gonadotropin deficiency. Brain Research, 2010, 1364, 3-9.	2.2	24
143	A man with a DAX1/NR0B1 mutation, normal puberty, and an intact hypothalamicâ€“pituitaryâ€“gonadal axis but deteriorating oligospermia during long-term follow-up. European Journal of Endocrinology, 2013, 168, K45-K50.	3.7	24
144	AIP mutations impair AhR signaling in pituitary adenoma patients fibroblasts and in GH3 cells. Endocrine-Related Cancer, 2016, 23, 433-443.	3.1	24

#	Article	IF	Citations
145	Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. Annales D'Endocrinologie, 2022, 83, 119-141.	1.4	23
146	Healthy birth after testicular extraction of sperm and <scp>ICSI</scp> from an azoospermic man with mild androgen insensitivity syndrome caused by an androgen receptor partial lossâ€ofâ€function mutation. Clinical Endocrinology, 2012, 77, 593-598.	2.4	22
147	Testis ultrasound in Klinefelter syndrome infertile men: making the diagnosis and avoiding inappropriate management. Abdominal Radiology, 2016, 41, 1596-1603.	2.1	22
148	PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease. JCI Insight, 2016, 1, e87958.	5.0	22
149	The Antigonadotropic Activity of a 19-Nor-Progesterone Derivative Is Exerted Both at the Hypothalamic and Pituitary Levels in Women. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4191-4196.	3.6	22
150	Society for Endocrinology <scp>UK</scp> guidance on the evaluation of suspected disorders of sexual development: emphasizing the opportunity to predict adolescent pubertal failure through a neonatal diagnosis of absent minipuberty. Clinical Endocrinology, 2017, 86, 305-306.	2.4	21
151	Congenital hypogonadotropic hypogonadism/Kallmann syndrome is associated with statural gain in both men and women: a monocentric study. European Journal of Endocrinology, 2020, 182, 185.	3.7	21
152	Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World Journal of Gastroenterology, 2009, 15, 328.	3.3	21
153	Primary adrenal and thyroid insufficiencies associated with hypopituitarism: a diagnostic challenge. Clinical Endocrinology, 1994, 40, 693-695.	2.4	20
154	Congenital Hypogonadotropic Hypogonadism with Anosmia and Gorlin Features Caused by a PTCH1 Mutation Reveals a New Candidate Gene for Kallmann Syndrome. Neuroendocrinology, 2021, 111, 99-114.	2.5	20
155	Benign cortisol-secreting adrenocortical adenomas produce small amounts of androgens. Clinical Endocrinology, 2007, 66, 778-788.	2.4	19
156	The Lack of Antitumor Effects of o,pâ€²DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment. Hormones and Cancer, 2014, 5, 312-323.	4.9	19
157	Ovarian macrocysts and gonadotropeâ€“ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. European Journal of Endocrinology, 2015, 172, 141-149.	3.7	19
158	Reversal of congenital hypogonadotropic hypogonadism in a man with Kallmann syndrome due to <scp>SOX</scp>10 mutation. Clinical Endocrinology, 2016, 85, 988-989.	2.4	19
159	Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo. FASEB Journal, 2018, 32, 4791-4797.	0.5	19
160	The antigonadotropic activity of progestins (19-nortestosterone and 19- norprogesterone derivatives) is not mediated through the androgen receptor. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 4218-4223.	3.6	19
161	Effects of Human Recombinant Luteinizing Hormone and Follicle-Stimulating Hormone in Patients with Acquired Hypogonadotropic Hypogonadism: Study of Sertoli and Leydig Cell Secretions and Interactions. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3239-3244.	3.6	19
162	Androgens and spermatogenesis. Annales D'Endocrinologie, 2022, 83, 155-158.	1.4	19

#	Article	IF	Citations
163	Germline Prolactin Receptor Mutation Is Not a Major Cause of Sporadic Prolactinoma in Humans. Neuroendocrinology, 2016, 103, 738-745.	2.5	17
164	Functional evidence implicating NOTCH2 missense mutations in primary ovarian insufficiency etiology. Human Mutation, 2019, 40, 25-30.	2.5	17
165	Flavor perception test: evaluation in patients with Kallmann syndrome. Endocrine, 2016, 52, 236-243.	2.3	16
166	R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism. PLoS ONE, 2013, 8, e69616.	2.5	16
167	Congenital hypogonadotropic hypogonadism and Kallmann syndrome as models for studying hormonal regulation of human testicular endocrine functions. Annales D'Endocrinologie, 2014, 75, 79-87.	1.4	15
168	Illicit Upregulation of Serotonin Signaling Pathway in Adrenals of Patients With High Plasma or Intra-Adrenal ACTH Levels. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4967-4980.	3.6	15
169	Primary amenorrhea revealing an occult progesterone-secreting ovarian tumor. Fertility and Sterility, 2008, 90, 1198.e1-1198.e5.	1.0	14
170	Effects of cortisol on the heart: characterization of myocardial involvement in cushing's disease by longitudinal cardiac MRI T1 mapping. Journal of Magnetic Resonance Imaging, 2017, 45, 147-156.	3.4	14
171	Natural and molecular history of prolactinoma: insights from aPrlr-/â€“ mouse model. Oncotarget, 2018, 9, 6144-6155.	1.8	14
172	Even after priming with ovarian steroids or pulsatile gonadotropin- releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea. Journal of Clinical Endocrinology and Metabolism, 1995, 80, 2102-2107.	3.6	14
173	Prenatal testosterone treatment potentiates the aggression-inhibiting effect of the neurosteroid dehydroepiandrosterone in female mice. Aggressive Behavior, 2001, 27, 130-138.	2.4	13
174	GnRH stimulation testing and serum inhibin B in males: insufficient specificity for discriminating between congenital hypogonadotropic hypogonadism from constitutional delay of growth and puberty. Human Reproduction, 2020, 35, 2312-2322.	0.9	13
175	Non-classic cytochrome P450 oxidoreductase deficiency strongly linked with menstrual cycle disorders and female infertility as primary manifestations. Human Reproduction, 2020, 35, 939-949.	0.9	13
176	Paradoxical Inhibitory Effect of Serotonin on Cortisol Production from Adrenocortical Lesions Causing Cushing's Syndrome. Endocrine Research, 2004, 30, 951-954.	1.2	12
177	Ovarian dysfunction by activating mutation of GS alpha: McCune-Albright syndrome as a model. Annales D'Endocrinologie, 2010, 71, 210-213.	1.4	12
178	Expression and characterization of androgen receptor coregulators, SRC-2 and HBO1, during human testis ontogenesis and in androgen signaling deficient patients. Molecular and Cellular Endocrinology, 2013, 375, 140-148.	3.2	12
179	Plasma 3 beta-hydroxy-delta 5-steroids in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 1994, 78, 299-304.	3.6	12
180	The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study. PLoS ONE, 2016, 11, e0152872.	2.5	12

#	Article	IF	Citations
181	Chromogranin A as serum marker of pituitary adenomas. Clinical Endocrinology, 2003, 59, 644-648.	2.4	11
182	Testicular histological and immunohistochemical aspects in a post-pubertal patient with 5 alpha-reductase type 2 deficiency: case report and review of the literature in a perspective of evaluation of potential fertility of these patients. BMC Endocrine Disorders, 2014, 14, 43.	2.2	11
183	Efficacy and tolerance of osilodrostat in patients with Cushingâ€™s syndrome due to adrenocortical carcinomas. European Journal of Endocrinology, 2022, 186, K1-K4.	3.7	11
184	Similarities and differences in the reproductive phenotypes of women with congenital hypogonadotrophic hypogonadism caused byGNRHRmutations and women with polycystic ovary syndrome. Human Reproduction, 2019, 34, 137-147.	0.9	10
185	Compromised Volumetric Bone Density and Microarchitecture in Men With Congenital Hypogonadotropic Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3312-e3326.	3.6	10
186	Treatment of acromegaly has substantial effects on body composition: a long-term follow-up study. European Journal of Endocrinology, 2022, 186, 173-181.	3.7	10
187	R-spondin2, a novel target of NOBOX: identification of variants in a cohort of women with primary ovarian insufficiency. Journal of Ovarian Research, 2017, 10, 51.	3.0	9
188	Expression, Hormonal Regulation, and Subcellular Localization of CCAAT/Enhancer-Binding Protein-Î² in Rat and Human Thyrocytes. Thyroid, 2005, 15, 197-204.	4.5	8
189	French law: what about a reasoned reimbursement of serum vitamin D assays?. Psychologie & Neuropsychiatrie Du Vieillissement, 2016, 14, 377-382.	0.2	7
190	Cortisol and Aldosterone Responses to Hypoglycemia and Na Depletion in Women With Non-Classic 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 55-64.	3.6	7
191	Pathogenic mosaic variants in congenital hypogonadotropic hypogonadism. Genetics in Medicine, 2020, 22, 1759-1767.	2.4	7
192	Galaxy Is a Suitable Bioinformatics Platform for the Molecular Diagnosis of Human Genetic Disorders Using High-Throughput Sequencing Data Analysis: Five Years of Experience in a Clinical Laboratory. Clinical Chemistry, 2022, 68, 313-321.	3.2	7
193	A mouse mutant strain highly resistant to methyl ?-carboline-3-carboxylate-induced seizures. Experimental Brain Research, 1996, 110, 28-35.	1.5	6
194	Ligand-dependent stabilization of androgen receptor in a novel mouse ST38c Sertoli cell line. Molecular and Cellular Endocrinology, 2014, 384, 32-42.	3.2	6
195	Foetal exposure to mitotane/Op'DDD: Postâ€natal study of four children. Clinical Endocrinology, 2018, 89, 805-812.	2.4	6
196	Prenatal management of fetal goiter alternating between hypothyroidism and hyperthyroidism in a mother with Gravesâ€™ disease. Clinical Case Reports (discontinued), 2021, 9, 2281-2284.	0.5	6
197	Reproductive Phenotypes in Men With Acquired or Congenital Hypogonadotropic Hypogonadism: A Comparative Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2812-e2824.	3.6	6
198	Pituitary stalk interruption and olfactory bulbs aplasia/hypoplasia in a man with Kallmann syndrome and reversible gonadotrope and somatotrope deficiencies. Endocrine, 2015, 49, 865-866.	2.3	5

#	Article	IF	Citations
199	Functional Characterization of Glucocorticoid Receptor Variants Is Required to Avoid Misinterpretation of NGS Data. Journal of the Endocrine Society, 2019, 3, 865-881.	0.2	5
200	Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushingâ€™s Disease: Final Results From the LINC 2 Study. Journal of the Endocrine Society, 2021, 5, A521-A522.	0.2	5
201	Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma. Reproductive BioMedicine Online, 2022, 44, 304-309.	2.4	5
202	Hypogonadotropic Hypogonadism and <i>GNRH1</i> Mutations in Mice and Humans. Frontiers of Hormone Research, 2010, 39, 111-120.	1.0	4
203	Bone mineral density in older patients with never-treated congenital hypogonadotropic hypogonadism. Endocrine, 2018, 59, 231-233.	2.3	4
204	A novel mutation in <scp>KHDRBS</scp>1 in a patient affected by primary ovarian insufficiency. Clinical Endocrinology, 2018, 89, 245-246.	2.4	4
205	Selective modification of a native protein in a patient tissue homogenate using palladium nanoparticles. Chemical Communications, 2019, 55, 15121-15124.	4.1	4
206	Epicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndrome. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3505-3514.	3.6	4
207	131I-Noriodocholesterol Uptake by Testicular Adrenal Rest Tumors in a Patient With Classical 21-Hydroxylase Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3956-3957.	3.6	3
208	Prolactin Assays and Regulation of Secretion: Animal and Human Data. Contemporary Endocrinology, 2019, , 55-78.	0.1	3
209	Serum insulin-like factor 3 quantification by LCâ€“MS/MS in male patients with hypogonadotropic hypogonadism and Klinefelter syndrome. Endocrine, 2021, 71, 578-585.	2.3	3
210	REMOVAL: Pelvic MRI in a 17-year-old XY girl with 5-alpha reductase deficiency and a homozygous Gly115Asp mutation in SRD5A2. Annales D'Endocrinologie, 2011, 72, 310-313.	1.4	2
211	Secondary amenorrhoea associated with high serum 17â€hydroxyprogesterone levels revealing a heterozygous <scp>CYP</scp>21A2 mutation in a woman with Addison disease. Clinical Endocrinology, 2015, 82, 620-622.	2.4	2
212	Le cycle ovarien : Endocrinologie de la reproduction. Medecine/Sciences, 1999, 15, 183.	0.2	2
213	Measurement of Plasma Free Luteinizing Hormone Â-Subunit in Women. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2293-2298.	3.6	2
214	Hypogonadismes hypogonadotrophiques chez l'homme. EMC - Endocrinologie - Nutrition, 2004, 1, 1-12.	0.0	1
215	Pharmacology of Hormone Replacement Therapy in Menopause. , 2012, , .		1
216	Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis. Case Reports in Endocrinology, 2019, 2019, 1-8.	0.4	1

#	Article	IF	Citations
217	Letter to the Editor: â€œLong-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomyâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e920-e921.	3.6	1
218	Does Genetic Susceptibility of the Gonadotropic Axis Explain the Variable Impact of Stressors Causing Functional Hypothalamic Amenorrhea?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1473-e1475.	3.6	1
219	The testis through the ages. Annales D'Endocrinologie, 2014, 75, 31.	1.4	0
220	Congenital Hypogonadotropic Hypogonadism in Females. , 2018, , 439-443.		0
221	Testosterone replacement therapy in puberty. Current Opinion in Endocrine and Metabolic Research, 2020, 14, 73-77.	1.4	0
222	The use of e-REC for capturing the occurrence of covid-19 infections in people with rare endocrine conditions. Endocrine Abstracts, 0, , .	0.0	0
223	Response to Letter to the Editor from Soghomonian: â€œEpicardial and Pericardial Adiposity Without Myocardial Steatosis in Cushing Syndromeâ€. Journal of Clinical Endocrinology and Metabolism, 2021, , .	3.6	0
224	Hypogonadisme hypogonadotrophique congÃ©nital chez la femme. , 2012, , 107-117.		0
225	Abstract 5754: Temozolomide therapy for progressive metastatic paraganglioma/pheochromocytoma: SDHB mutation as a prognosis biomarker for efficacy. , 2012, , .		0
226	Hypogonadisme hypogonadotrophique congÃ©nital isolÃ© et syndrome de Kallmann chez la femme : diagnostic, exploration et traitement en 2019. , 2019, , 111-127.		0
227	MON-244 GnRH Test Does Not Efficiently Discriminate Congenital Isolated Hypogonadotropic Hypogonadism from Constitutional Delay of Growth and Puberty in Males. Journal of the Endocrine Society, 2019, 3, .	0.2	0
228	SAT-010 Non-Classic POR Deficiency as a Cause of Menstrual Disorders & Infertility. Journal of the Endocrine Society, 2020, 4, .	0.2	0
229	Exome sequencing as a tool for detecting point mutations and deletions in patients with hypogonadotropic hypogonadism. Journal of Clinical Endocrinology and Metabolism, 0, , .	3.6	0